GLP-1 for bridging of hyperglycaemia during cardiac surgery: a randomized controlled trial - The GLOBE trial

Academic Medical Center0 个研究点目标入组 274 人开始时间: 2017年1月30日最近更新: 2019年6月30日

试验速览

暂无简介。

•Adult patients, aged 18-80 years (inclusive),
•No known diabetes mellitus, or
•Known diabetes mellitus type 2 on oral glucose lowering medication, diet or total daily insulin dose =0.5 IU/kg
•Scheduled for an elective cardiac surgical procedure.
•Informed consent obtained before any trial-related activities are carried out.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 174
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

•Diabetes mellitus type 1
•Emergency surgery
•Receiving oral corticosteroid therapy
•History of pancreatic surgery or acute or chronic pancreatitis
•Personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia23 syndrome type 2 (MEN2)
•Heart failure NYHA class IV
•Serum-creatinine = 133 µmol l-1 for males and = 115 µmol l-1 for females, measured within 6 months before date of surgery.
•Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
•Current treatment with GLP-1 analogues
•Known or suspected allergy to trial products or other drugs in the same class

发起方

Academic Medical Center